Fuji Pharma (4554) · InitiativeRestated
Development and manufacture of high-complexity products using next-generation technologies
First written in FY2020. 2 of 3 entries say "Restated". Latest entry: FY2022.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Strengthening Development and Manufacturing Capabilities for Technically Challenging Pharmaceuticals Through Next-Generation TechnologiesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「The company has technologies for developing and manufacturing complex products and will continue to develop and provide high-quality pharmaceuticals.」
It continues to pursue the policy of providing pharmaceuticals through technologies for developing and manufacturing complex products. - FY2021RestatedAnnual report
「The company has technologies for developing and manufacturing complex products and will continue to develop and provide high-quality pharmaceuticals.」
It continues to pursue the policy of providing high-quality pharmaceuticals through technologies for developing and manufacturing complex products. - FY2020First statedAnnual report
「The company has technologies for developing and manufacturing complex products and will continue to develop and provide high-quality pharmaceuticals.」
It newly describes the acquisition and use of technologies for developing and manufacturing complex products as a next-generation technology strategy.